Lead Product(s): BI 456906
Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Zealand Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.